Changeflow GovPing Healthcare & Life Sciences Optogenetic Immunotherapy Patent EP4069728A1 - ...
Priority review Rule Added Final

Optogenetic Immunotherapy Patent EP4069728A1 - University of Massachusetts

Favicon for changeflow.com EPO Patent Bulletin - Biotech (C12N)
Published
Detected
Email

Summary

The European Patent Office published patent application EP4069728A1 for compositions and methods related to optogenetic immunotherapy on April 15, 2026. The applicants are University of Massachusetts, with inventors HAN, Gang and ZHOU, Yubin. The published application covers IPC classifications including C07K, C12N, and A61P therapeutic categories, designating all EPO member states for potential patent protection.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 53 changes logged to date.

What changed

The European Patent Office published patent application EP4069728A1 on April 15, 2026, covering compositions and methods for optogenetic immunotherapy. The application designates all EPO member states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR) for potential patent protection.

Competitors developing optogenetic or cellular immunotherapy technologies should review the published claims for potential overlap with their own R&D programs. The publication establishes priority rights for University of Massachusetts as of the filing date, and the 18-month examination period will determine whether the patent proceeds to grant.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

COMPOSITIONS AND METHODS FOR OPTOGENETIC IMMUNOTHERAPY

Publication EP4069728A1 Kind: A1 Apr 15, 2026

Applicants

University of Massachusetts

Inventors

HAN, Gang, ZHOU, Yubin

IPC Classifications

C07K 14/705 20060101AFI20231117BHEP C07K 14/725 20060101ALI20231117BHEP C07K 16/00 20060101ALI20231117BHEP C12N 5/0783 20100101ALI20231117BHEP A61P 35/00 20060101ALI20231117BHEP A61K 39/00 20060101ALI20231117BHEP B82Y 20/00 20110101ALI20231117BHEP C07K 16/28 20060101ALI20231117BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
International
Legal weight
Binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Pharmaceutical companies Biotechnology companies Research institutions
Industry sector
3254.1 Biotechnology
Activity scope
Patent publication IP rights establishment Immunotherapy research
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!